Cover Image
市場調查報告書

MediPoint:冠狀動脈支架 - 歐盟市場分析與預測

MediPoint: Coronary Stents - EU Analysis and Market Forecasts

出版商 GlobalData 商品編碼 320351
出版日期 內容資訊 英文 376 Pages
訂單完成後即時交付
價格
Back to Top
MediPoint:冠狀動脈支架 - 歐盟市場分析與預測 MediPoint: Coronary Stents - EU Analysis and Market Forecasts
出版日期: 2014年11月28日 內容資訊: 英文 376 Pages
簡介

從2011年到2020年的EU地區的冠狀動脈支架市場,預計以負0.5%的年複合成長率成長。和美國同樣,在市場中佔藥物釋放型血管支架最大的佔有率,有裸金屬的4倍規模。今後的藥物釋放型血管支架市場,由於結果改善和Low-profile系統及下一代支架的開發,複數回的手術必要性低的成本降低等,以緩慢的速度成長。

本報告提供EU地區的冠狀動脈支架市場相關調查、冠狀動脈支架種類與概要、冠狀動脈支架置入的指南、模式、未滿足需求、支架市場的各種影響因素及市場機會分析、企業及企業間的配合措施、產品及產品開發趨勢、主要企業簡介、各國的趨勢、市場收益的變化與預測等彙整資料。

第1章 目錄

第2章 簡介

第3章 產業概要

  • 疾病概要
  • 臨床結果
    • 治療的指南
    • 治療的模式
  • 治療趨勢
    • EU
  • 市場進入
    • 法律規章相關的流程
    • 醫生決策的流程
    • GPO(團購組織)所扮演的角色
    • 臨床資料的缺乏
    • 地區層級的控制
    • 成本相關考察
    • 償付趨勢
  • 法規上的課題/回收
    • 法規上的課題
    • 產品回收
  • M&A、主要聯盟
    • Medtronic和Covidien
    • Arterial Remodeling Technologies和Terumo Corporation
    • MicroPort Scientific Corporation和Cordis Corporation
    • Alvimedica和CID
    • ITGI Medical和Vascular Solutions
    • Terumo Corporation和Onset Medical Corporation
    • Atrium Medical和Getinge Group
    • C.R.Bard和ClearStream Technologies
    • Biosensors International and Devax、CardioMind、JW Medical Systems
    • CeloNova Biosciences和Nexeon MedSystems
    • Medtronic和Invatec
    • Micell Technologies和Maxcor Lifescience
    • Boston Scientific Corporation和Guidant Corporation
    • Abbott Vascular和Guidant Corporation
    • Kaneka和Astellas Pharma Inc.
  • 冠狀動脈疾病的經濟影響
    • EU
  • 冠狀動脈疾病的治療費

第4章 未滿足需求

  • 特異性病變的更佳臨床結果的必要性
    • 慢性完全閉塞
    • 小血管冠狀動脈病變
    • 重鈣化的無法通過、擴張的病變
    • 分叉病變
    • 隱靜脈移植手術
  • 球囊血管成形術的障礙消除的機制
  • 支架置入之後的心肌梗塞
  • 恆久性聚合物的消除
  • 支架內的狹窄復發
  • 支架內支架
  • 長期的抗血小板藥的聯合治療
  • 均質的藥物分佈不足
  • 支架內皮層化的延遲
  • 陰性血管的重塑
  • 對特定患者層有效的治療方法的必要性
  • 冠狀動脈繞道手術移植術的併發症的應對

第5章 市場機會分析

  • 支架設計/平台的改善
    • 支架塗層技術
    • 生物可吸收支架技術
    • 抗增生性藥物和熔析動態
  • 混合支架系統
  • 對困難的冠狀動脈疾病的有效治療方法
    • 慢性完全閉塞
    • 小血管疾病
    • 分叉病變
    • 廣泛性動脈粥狀硬化性疾病
    • 隱靜脈移植手術
    • 急性心肌梗塞
  • 困難的患者層的應對
  • 新興市場

第6章 推動市場要素、障礙、替代

  • 推動市場要素
    • 疾病的盛行率的上升
    • 對困難的冠狀動脈疾病有效的治療方法
    • 支架技術的創新
    • 生物可吸收支架的開發
    • 排除長期的抗血小板藥聯合治療的必要性
    • 潛在成本的削減
    • 正確的支架置入的影像診斷療法的使用
    • 新興市場的支架引進
    • 在美國及日本的生物可吸收支架的銷售
  • 市場障礙
    • Overstenting相關疑慮
    • 藥物釋放型血管支架置入後的併發症
    • 手術中的有害活動的風險
    • 生物可吸收支架的吸收的延遲
    • 償付的不足
    • 醫療費削減及償付
    • 風險企業資金的可用性
    • 醫療設備物品稅
  • 替代
    • 藥物釋放型球囊
    • 液體藥物輸送用導管

第7章 競爭分析

  • 概要
  • 冠狀動脈支架的技術開發的趨勢
    • 傳統金屬支架的開發
    • 藥物釋放型血管支架的開發
    • 生物可吸收支架的開發
    • 覆膜支架的開發
    • 冠狀動脈支架技術:SWOT分析
  • 企業的市場佔有率:各地區
    • EU

第8章 開發中產品

  • 概要
  • 開發中產品:各開發階段
  • 開發中產品簡介
    • 生物可吸收支架
    • 其他類型的血管支架

第9章 臨床試驗分析

  • 概要
  • 關注的臨床試驗
    • 最新、新世代的藥物釋放型血管支架的評估
    • 生物可吸收支架的臨床試驗
    • 對困難的冠狀動脈症狀患者的支架置入的評估
    • 亞太地區的患者層的目標化

第10章 現在及未來的企業

  • 概要
  • 企業策略趨勢
  • 企業簡介
    • Abbott Vascular
    • Boston Scientific Corporation
    • Medtronic
    • Alvimedica
    • Amaranth Medical
    • amg International
    • Arterial Remodeling Technologies
    • B. Braun
    • Balton
    • Biosensors International
    • Biotronik
    • Blue Medical
    • Cardionovum
    • C.R.Bard
    • Elixir Medical Corporation
    • eucatech AG
    • Hexacath
    • IRAMED
    • JW Medical Systems
    • 京都醫療設計
    • Lepu Medical Technology
    • MicroPort Scientific Corporation
    • Minvasys
    • MIV Therapeutics
    • Opto Circuits
    • OrbusNeich Medical
    • Relisys Medical Devices
    • REVA Medical
    • Sahajanand Medical Technologies
    • STENTYS
    • Terumo Corporation
    • Translumina
    • Vascular Concepts
    • 其他

第11章 市場預測

  • 各市場區隔
    • 概要
    • 藥物釋放型血管支架市場
    • 傳統金屬支架市場
    • 新的支架技術
  • 各適應症
  • 各地區
    • EU5個國家

第12章 附錄

圖表清單

目錄
Product Code: GDME1118CFR

The global coronary stents market is a dynamic, double-digit market that is saturated with numerous players developing innovative technologies. Rapid advances in the field of interventional cardiology along with the development of minimally invasive techniques have greatly expanded the potential of therapeutic applications. Coronary stents including bare metal, drug-eluting, covered and bioabsorbable stents can be used to treat coronary artery disease, and optimize outcomes.

The coronary stents market in the EU has an overall negative CAGR of 0.5% over the forecast period from 2011-2020. Similar to the US, the DES market in the EU has the largest share, where the DES market is four times that of the BMS market. Moving forward, GlobalData believes that the DES market will grow slowly due to the improved outcomes, the development of low-profile systems and the next generation of DES, and cost-savings due to the reduced need for repeat intervention.

In the EU, there is a strong dependency on reimbursement, which can vary between nations. German reimbursement has generally been strong for medical devices, and has been less of a problem. However, the other countries are keen to follow clinical outcomes carefully for adoption and product usage in order to obtain reimbursement.

Scope

  • An overview of Coronary Stents, which includes epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines.
  • Annualized EU Coronary Stents market revenue and future forecasts from 2011 to 2013, forecast for 7 years to 2020.
  • Investigation of current and future market competition for Coronary Stents.
  • Insightful review of the key industry drivers, restraints and challenges as well as predicted impact of key events.
  • Competitor assessment including device approval analysis and device sales forecasts.
  • Marketed and pipeline product profiles covering efficiency, safety, clinical study details, device approvals, product positioning and device sales forecast.
  • Analysis of unmet needs within the market and opportunities for future players.
  • Technology trends evaluation to assess strength of pipeline.
  • An overview of all devices in development including clinical study details, design and material selection considerations, efficacy reports, and device approval timelines.
  • Company profiles including business description, financial overview and SWOT analysis.
  • Coverage of key market players.
  • Strategic assessment of the Coronary Stents sector through market impact analysis, future market scenario and company analysis.
  • Direct quotes from Key Opinion Leaders (KOL) as well as doctors

Reasons to buy

  • Understand the trends shaping and driving the EU Coronary Stents market.
  • Realize device preferences of physicians who have performed the tests already.
  • Access market sizing, forecasts and quantified growth opportunities in the US Coronary Stents market through 2018.
  • Quantify candidate patient populations to better design product pricing & launch plans.
  • Drive revenues, formulate effective sales and marketing strategies and gain in-depth understanding of the competitive landscape.
  • Perform benchmarking analysis of growth opportunities against currently marketed products.
  • Assess competitiveness of products in market by understanding the strengths and weaknesses of current competition.
  • Take a comprehensive look at the market's device pipeline and identify promising, paradigm-shifting products.
  • Create an effective counter-strategy to gain a competitive advantage against those currently in the market.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present the best opportunities for growth.
  • What's the next big thing in the EU Coronary Stents market landscape Identify, understand and capitalize.

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Catalyst
  • 2.2. Related Reports

3. Industry Overview

  • 3.1. Disease Overview
  • 3.2. Clinical Outcomes
    • 3.2.1. Treatment Guidelines
    • 3.2.2. Treatment Modalities
  • 3.3. Procedure Trends
    • 3.3.1. European Union
  • 3.4. Market Access
    • 3.4.1. Regulatory Process
    • 3.4.2. Physician Decision-Making Process
    • 3.4.3. Role of Group Purchasing Organizations
    • 3.4.4. Lack of Clinical Data
    • 3.4.5. Regional-Level Control
    • 3.4.6. Cost Considerations
    • 3.4.7. Reimbursement Trends
  • 3.5. Regulatory Issues/Recalls
    • 3.5.1. Regulatory Issues
    • 3.5.2. Product Recalls
  • 3.6. Mergers and Acquisitions/ Key Partnerships
    • 3.6.1. Medtronic and Covidien
    • 3.6.2. Arterial Remodeling Technologies and Terumo Corporation
    • 3.6.3. MicroPort Scientific Corporation and Cordis Corporation
    • 3.6.4. Alvimedica and CID
    • 3.6.5. ITGI Medical and Vascular Solutions
    • 3.6.6. Terumo Corporation and Onset Medical Corporation
    • 3.6.7. Atrium Medical and Getinge Group
    • 3.6.8. C.R. Bard and ClearStream Technologies
    • 3.6.9. Biosensors International and Devax, CardioMind, and JW Medical Systems
    • 3.6.10. CeloNova Biosciences and Nexeon MedSystems
    • 3.6.11. Medtronic and Invatec
    • 3.6.12. Micell Technologies and Maxcor Lifescience
    • 3.6.13. Boston Scientific Corporation and Guidant Corporation
    • 3.6.14. Abbott Vascular and Guidant Corporation
    • 3.6.15. Kaneka Corporation and Fujisawa Pharmaceuticals
  • 3.7. Economic Impact of Coronary Artery Disease
    • 3.7.1. European Union
  • 3.8. Treatment Costs for Coronary Artery Disease

4. Unmet Needs

  • 4.1. Need for Better Clinical Outcomes in Specific Lesions
    • 4.1.1. Chronic Total Occlusions
    • 4.1.2. Small-Vessel Coronary Lesions
    • 4.1.3. Heavily-Calcified and Uncrossable/Undilatable Lesions
    • 4.1.4. Bifurcation Lesions
    • 4.1.5. Saphenous Vein Graft Intervention
  • 4.2. Eliminating Mechanisms of Failure With Balloon Angioplasty
  • 4.3. Late Myocardial Infarction After Stenting
  • 4.4. Eliminating the Permanent Polymer
  • 4.5. In-Stent Restenosis
  • 4.6. Stent-In-Stent Procedures
  • 4.7. Prolonged Dual Antiplatelet Therapy
  • 4.8. Lack of Homogenous Drug Distribution
  • 4.9. Delayed Stent Endothelialization
  • 4.10. Negative Vessel Remodeling
  • 4.11. Need for Effective Therapy for Specific Patient Populations
  • 4.12. Addressing the Complications of Coronary Artery Bypass Grafting

5. Market Opportunity Analysis

  • 5.1. Improve Stent Design/Platform
    • 5.1.1. Stent Coating Technology
    • 5.1.2. Bioabsorbable Stent Technology
    • 5.1.3. Antiproliferative Drug and Elution Kinetics
  • 5.2. Hybrid Stent Systems
  • 5.3. Effective Therapies for Challenging Coronary Indications
    • 5.3.1. Chronic Total Occlusions
    • 5.3.2. Small-Vessel Disease
    • 5.3.3. Bifurcation Lesions
    • 5.3.4. Diffuse Atherosclerotic Disease
    • 5.3.5. Saphenous Vein Graft Intervention
    • 5.3.6. Acute Myocardial Infarction
  • 5.4. Target Challenging Patient Populations
  • 5.5. Emerging Markets

6. Market Drivers, Barriers, and Substitutes

  • 6.1. Market Drivers
    • 6.1.1. Rising Prevalence of Disease
    • 6.1.2. Viable Treatment for Challenging Coronary Indications
    • 6.1.3. Innovations in Stent Technology
    • 6.1.4. Development of Bioabsorbable Stents
    • 6.1.5. Reduce the Need for Prolonged Dual Antiplatelet Therapy
    • 6.1.6. Potential Cost Savings
    • 6.1.7. Use of Imaging Modalities for Accurate Stent Placement
    • 6.1.8. Adoption of Stents in the Emerging Markets
    • 6.1.9. Launch of Bioabsorbable Stents in US and Japan
  • 6.2. Market Barriers
    • 6.2.1. Concerns Regarding Overstenting
    • 6.2.2. Post-ProceduraI Complications of Drug-Eluting Stenting
    • 6.2.3. Risk of Perioperative Adverse Cardiac Events Post-Stenting
    • 6.2.4. Slow Adoption of Bioabsorbable Stents
    • 6.2.5. Lack of Reimbursement
    • 6.2.6. Healthcare Cost-Cutting and Reimbursement
    • 6.2.7. Availability of Venture Capital
    • 6.2.8. Medical Device Excise Tax
  • 6.3. Market Substitutes
    • 6.3.1. Drug-Eluting Balloons
    • 6.3.2. Liquid Drug Delivery Catheter

7. Competitive Assessment

  • 7.1. Overview
  • 7.2. Trends in Coronary Stent Technology Development
    • 7.2.1. Development of Bare Metal Stents
    • 7.2.2. Development of Drug-Eluting Stents
    • 7.2.3. Development of Bioabsorbable Stents
    • 7.2.4. Development of Covered Stents
    • 7.2.5. Coronary Stent Technology SWOT Analysis
  • 7.3. Regional Company Market Share
    • 7.3.1. EU Market Share

8. Pipeline Products

  • 8.1. Overview
  • 8.2. Pipeline by Stage of Development
  • 8.3. Pipeline Product Profiles
    • 8.3.1. Bioabsorbable Stents
    • 8.3.2. Other Types of Vascular Stents

9. Clinical Trial Analysis

  • 9.1. Overview
  • 9.2. Clinical Trials to Watch
    • 9.2.1. Evaluating the Latest and New Generation of Drug-Eluting Stents
    • 9.2.2. Bioabsorbable Stent Clinical Trials
    • 9.2.3. Evaluating Stenting in Challenging Coronary Indications/Patient Populations
    • 9.2.4. Targeting Patient Populations in the APAC Region

10. Current and Future Players

  • 10.1. Overview
  • 10.2. Trends in Corporate Strategy
  • 10.3. Company Profiles
    • 10.3.1. Abbott Vascular
    • 10.3.2. Boston Scientific Corporation
    • 10.3.3. Medtronic
    • 10.3.4. Alvimedica
    • 10.3.5. Amaranth Medical
    • 10.3.6. amg International
    • 10.3.7. Arterial Remodeling Technologies
    • 10.3.8. B. Braun
    • 10.3.9. Balton
    • 10.3.10. Biosensors International
    • 10.3.11. Biotronik
    • 10.3.12. Blue Medical
    • 10.3.13. Cardionovum
    • 10.3.14. C.R. Bard
    • 10.3.15. Elixir Medical Corporation
    • 10.3.16. eucatech AG
    • 10.3.17. Hexacath
    • 10.3.18. IRAMED
    • 10.3.19. JW Medical Systems
    • 10.3.20. Kyoto Medical Planning
    • 10.3.21. Lepu Medical Technology
    • 10.3.22. MicroPort Scientific Corporation
    • 10.3.23. Minvasys
    • 10.3.24. MIV Therapeutics
    • 10.3.25. Opto Circuits
    • 10.3.26. OrbusNeich Medical
    • 10.3.27. Relisys Medical Devices
    • 10.3.28. REVA Medical
    • 10.3.29. Sahajanand Medical Technologies
    • 10.3.30. STENTYS
    • 10.3.31. Terumo Corporation
    • 10.3.32. Translumina
    • 10.3.33. Vascular Concepts
    • 10.3.34. Other Companies

11. Market Outlook

  • 11.1. By Market Segment
    • 11.1.1. Overview
    • 11.1.2. Drug-Eluting Stent Market
    • 11.1.3. Bare Metal Stent Market
    • 11.1.4. Emerging Stent Technologies
  • 11.2. By Indication
  • 11.3. By Geography
    • 11.3.1. 5EU

12. Appendix

  • 12.1. Bibliography
  • 12.2. Abbreviations
  • 12.3. Report Methodology
    • 12.3.1. Overview
    • 12.3.2. Coverage
    • 12.3.3. Secondary Research
  • 12.4. Physicians and Specialists Included in This Study
    • 12.4.1. Praveen Chandra, MD, DM, FESC, FSCAI, FAPSCI
    • 12.4.2. Bernado Cortese, MD, FESC
    • 12.4.3. Ricardo A. Costa, MD
    • 12.4.4. Thomas Cuisset, MD, PhD, FESC
    • 12.4.5. Nobuyuki Komiyama, MD, PhD, FACC, FJCC
    • 12.4.6. Roger J. Laham, MD
    • 12.4.7. Mark W. Mewissen, MD
    • 12.4.8. Gary S. Mintz, MD
    • 12.4.9. Tudor C. Poerner, MD
    • 12.4.10. David Ramsdale, MD, PhD
    • 12.4.11. Gregory A. Sgueglia, MD, PhD
    • 12.4.12. Madhukar Shahi, MD
    • 12.4.13. Takehiro Yamashita, MD, PhD, FACC
  • 12.5. Primary Research
    • 12.5.1. Primary Research - Key Opinion Leader Interviews
    • 12.5.2. Primary Research Interviews- Physician and Industry Participants
    • 12.5.3. Physican Survey
    • 12.5.4. Expert Panel Validation
  • 12.6. Forecasting Methodology
  • 12.7. About the Authors
    • 12.7.1. Analysts
    • 12.7.2. Global Head of Healthcare
  • 12.8. About MediPoint
  • 12.9. About GlobalData
  • 12.10. Disclaimer

List of Tables

  • Table 1: ACCF/AHA Treatment Guidelines to Improve the Symptoms of CAD*
  • Table 2: Types of CABG
  • Table 3: Complications of CABG
  • Table 4: Drugs Incorporated Into DES
  • Table 5: Types of Lesions Treated Using Atherectomy
  • Table 6: GPOs in the US and EU
  • Table 7: Direct and Indirect Healthcare Costs of CAD
  • Table 8: Healthcare Expenditures ($bn) for CAD in the 5EU, 2006
  • Table 9: US Mean Hospital Costs* ($US) for Cardiac Revascularization Procedures, 2011-2020
  • Table 10: Coronary Stent Technology SWOT Analysis, 2014
  • Table 11: Global Coronary Stent Pipeline Products, 2014
  • Table 12: ART18Z SWOT Analysis, 2014
  • Table 13: DREAMS SWOT Analysis, 2014
  • Table 14: Fantom SWOT Analysis, 2014
  • Table 15: Fortitude SWOT Analysis, 2014
  • Table 16: Ideal BioStent SWOT Analysis, 2014
  • Table 17: Igaki-Tamai Stent SWOT Analysis, 2014
  • Table 18: ON-AVS SWOT Analysis, 2014
  • Table 19: Other Companies Developing BAS, 2014
  • Table 20: FOCUS np Eluting Stent SWOT Analysis, 2014
  • Table 21: STENTYS Sirolimus-Eluting Stent SWOT Analysis, 2014
  • Table 22: Svelte Drug-Eluting Stent SWOT Analysis, 2014
  • Table 23: Clinical Trials Evaluating the Latest and New Generation of DES, 2014
  • Table 24: Clinical Trials Evaluating Stenting in Challenging CAD Indications/Patient Populations, 2014
  • Table 25: Clinical Trials Evaluating Coronary Stenting in APAC Patient Populations, 2014
  • Table 26: Abbott Vascular Company Profile
  • Table 27: Abbott Vascular Coronary Stent Marketed Products
  • Table 28: Abbott Vascular Coronary Stent Product Portfolio SWOT Analysis, 2014
  • Table 29: Abbott Vascular SWOT Analysis, 2014
  • Table 30: Boston Scientific Corporation Company Profile
  • Table 31: Boston Scientific Coronary Stent Marketed Products
  • Table 32: Boston Scientific Coronary Stent Product Portfolio SWOT Analysis, 2014
  • Table 33: Boston Scientific Corporation SWOT Analysis, 2014
  • Table 34: Medtronic Company Profile
  • Table 35: Medtronic Coronary Stent Marketed Products
  • Table 36: Medtronic Coronary Stent Product Portfolio SWOT Analysis, 2014
  • Table 37: Medtronic SWOT Analysis, 2014
  • Table 38: Alvimedica Company Profile
  • Table 39: Alvimedica Coronary Stent Marketed Products
  • Table 40: Alvimedica Coronary Stent Product Portfolio SWOT Analysis, 2014
  • Table 41: Alvimedica SWOT Analysis, 2014
  • Table 42: Amaranth Medical Company Profile
  • Table 43: Amaranth Medical Coronary Stent Pipeline Product
  • Table 44: Amaranth Medical Coronary Stent Product Portfolio SWOT Analysis, 2014
  • Table 45: Amaranth Medical SWOT Analysis, 2014
  • Table 46: amg International Company Profile
  • Table 47: amg International Coronary Stent Marketed Products
  • Table 48: amg International Coronary Stent Product Portfolio SWOT Analysis, 2014
  • Table 49: amg International SWOT Analysis, 2014
  • Table 50: Arterial Remodeling Technologies Company Profile
  • Table 51: Arterial Remodeling Technologies Coronary Stent Pipeline Product
  • Table 52: Arterial Remodeling Technologies Coronary Stent Product Portfolio SWOT Analysis, 2014
  • Table 53: Arterial Remodeling Technologies SWOT Analysis, 2014
  • Table 54: B. Braun Company Profile
  • Table 55: B. Braun Coronary Stent Marketed Products
  • Table 56: B. Braun Coronary Stent Product Portfolio SWOT Analysis, 2014
  • Table 57: B. Braun SWOT Analysis, 2014
  • Table 58: Balton Company Profile
  • Table 59: Balton Coronary Stent Marketed Products
  • Table 60: BALTON Coronary Stent Product Portfolio SWOT Analysis, 2014
  • Table 61: Balton SWOT Analysis, 2014
  • Table 62: Biosensors International Company Profile
  • Table 63: Biosensors International Coronary Stent Marketed Products
  • Table 64: Biosensors International Coronary Stent Product Portfolio SWOT Analysis, 2014
  • Table 65: Biosensors International SWOT Analysis, 2014
  • Table 66: Biotronik Company Profile
  • Table 67: Biotronik Coronary Stent Marketed and Pipeline Products
  • Table 68: Biotronik Coronary Stent Product Portfolio SWOT Analysis, 2014
  • Table 69: Biotronik SWOT Analysis, 2014
  • Table 70: Blue Medical Company Profile
  • Table 71: Blue Medical Coronary Stent Marketed Products
  • Table 72: Blue Medical Coronary Stent Product Portfolio SWOT Analysis, 2014
  • Table 73: Blue Medical SWOT Analysis, 2014
  • Table 74: Cardionovum Company Profile
  • Table 75: Cardionovum Coronary Stent Marketed and Pipeline Products
  • Table 76: Cardionovum Coronary Stent Product Portfolio SWOT Analysis, 2014
  • Table 77: Cardionovum SWOT Analysis, 2014
  • Table 78: C.R. Bard Company Profile
  • Table 79: ClearStream Technologies Coronary Stent Marketed Products
  • Table 80: C.R. Bard Coronary Stent Product Portfolio SWOT Analysis, 2014
  • Table 81: C.R. Bard SWOT Analysis, 2014
  • Table 82: Elixir Medical Corporation Company Profile
  • Table 83: Elixir Medical Corporation Coronary Stent Marketed Products
  • Table 84: Elixir Medical Corporation Coronary Stent Product Portfolio SWOT Analysis, 2014
  • Table 85: Elixir Medical Corporation SWOT Analysis, 2014
  • Table 86: eucatech Profile
  • Table 87: eucatech Coronary Stent Marketed Products
  • Table 88: eucatech Coronary Stent Product Portfolio SWOT Analysis, 2014
  • Table 89: eucatech SWOT Analysis, 2014
  • Table 90: Hexacath Company Profile
  • Table 91: Hexacath Coronary Stent Marketed Products
  • Table 92: Hexacath Coronary Stent Product Portfolio SWOT Analysis, 2014
  • Table 93: Hexacath SWOT Analysis, 2014
  • Table 94: IRAMED Company Profile
  • Table 95: IRAMED Coronary Stent Marketed Products
  • Table 96: IRAMED Coronary Stent Product Portfolio SWOT Analysis, 2014
  • Table 97: IRAMED SWOT Analysis, 2014
  • Table 98: JW Medical Systems Company Profile
  • Table 99: JW Medical Systems Coronary Stent Marketed Product
  • Table 100: JW Medical Systems' Coronary Stent Product Portfolio SWOT Analysis, 2014
  • Table 101: JW Medical Systems SWOT Analysis, 2014
  • Table 102: Kyoto Medical Planning Company Profile
  • Table 103: Kyoto Medical Planning Coronary Stent Pipeline Product
  • Table 104: Kyoto Medical Planning Coronary Stent Product Portfolio SWOT Analysis, 2014
  • Table 105: Kyoto Medical Planning SWOT Analysis, 2014
  • Table 106: Lepu Medical Technology Company Profile
  • Table 107: Lepu Medical Technology Coronary Stent Marketed and Pipeline Products
  • Table 108: Lepu Medical Technology Coronary Stent Product Portfolio SWOT Analysis, 2014
  • Table 109: Lepu Medical Technology SWOT Analysis, 2014
  • Table 110: MicroPort Scientific Corporation Company Profile
  • Table 111: MicroPort Scientific Corporation Coronary Stent Marketed Products
  • Table 112: MicroPort Scientific Corporation Coronary Stent Product Portfolio SWOT Analysis, 2014
  • Table 113: MicroPort Scientific Corporation SWOT Analysis, 2014
  • Table 114: Minvasys Company Profile
  • Table 115: Minvasys Coronary Stent Marketed and Pipeline Products
  • Table 116: Minvasys Coronary Stent Product Portfolio SWOT Analysis, 2014
  • Table 117: Minvasys SWOT Analysis, 2014
  • Table 118: MIV Therapeutics Company Profile
  • Table 119: MIV Therapeutics Coronary Stent Marketed Products
  • Table 120: MIV Therapeutics Coronary Stent Product Portfolio SWOT Analysis, 2014
  • Table 121: MIV Therapeutics SWOT Analysis, 2014
  • Table 122: Opto Circuits Company Profile
  • Table 123: Opto Circuits Coronary Stent Marketed Products
  • Table 124: Opto Circuits Coronary Stent Product Portfolio SWOT Analysis, 2014
  • Table 125: Opto Circuits SWOT Analysis, 2014
  • Table 126: OrbusNeich Medical Company Profile
  • Table 127: OrbusNeich Medical Coronary Stent Marketed and Pipeline Products
  • Table 128: OrbusNeich Medical Coronary Stent Product Portfolio SWOT Analysis, 2014
  • Table 129: OrbusNeich Medical SWOT Analysis, 2014
  • Table 130: Relisys Medical Devices Company Profile
  • Table 131: Relisys Medical Devices Coronary Stent Marketed Products
  • Table 132: Relisys Medical Devices Coronary Stent Product Portfolio SWOT Analysis, 2014
  • Table 133: Relisys Medical Devices SWOT Analysis, 2014
  • Table 134: REVA Medical Company Profile
  • Table 135: REVA Medical Coronary Stent Pipeline Product
  • Table 136: REVA Medical Coronary Stent Product Portfolio SWOT Analysis, 2014
  • Table 137: REVA Medical SWOT Analysis, 2014
  • Table 138: Sahajanand Medical Technologies Company Profile
  • Table 139: Sahajanand Medical Technologies Coronary Stent Marketed and Pipeline Products
  • Table 140: Sahajanand Medical Technologies Coronary Stent Product Portfolio SWOT Analysis, 2014
  • Table 141: Sahajanand Medical Technologies SWOT Analysis, 2014
  • Table 142: STENTYS Company Profile
  • Table 143: STENTYS Coronary Stent Marketed and Pipeline Products
  • Table 144: STENTYS Coronary Stent Product Portfolio SWOT Analysis, 2014
  • Table 145: STENTYS SWOT Analysis, 2014
  • Table 146: Terumo Corporation Company Profile
  • Table 147: Terumo Corporation Coronary Stent Marketed and Pipeline Products
  • Table 148: Terumo Corporation Coronary Stent Product Portfolio SWOT Analysis, 2014
  • Table 149: Terumo Corporation SWOT Analysis, 2014
  • Table 150: Translumina Company Profile
  • Table 151: Translumina Coronary Stent Marketed Products
  • Table 152: Translumina Coronary Stent Product Portfolio SWOT Analysis, 2014
  • Table 153: Translumina SWOT Analysis, 2014
  • Table 154: Vascular Concepts Company Profile
  • Table 155: Vascular Concepts Coronary Stent Marketed Products
  • Table 156: Vascular Concepts Coronary Stent Product Portfolio SWOT Analysis, 2014
  • Table 157: Vascular Concepts SWOT Analysis, 2014
  • Table 158: Other Companies in the Coronary Stent Market, North America, 2014
  • Table 159: Other Companies in the Coronary Stent Market, EU, 2014
  • Table 160: Other Companies in the Coronary Stent Market, APAC, 2014
  • Table 161: Other Companies in the Coronary Stent Market, South Africa and South America, 2014
  • Table 162: Global Coronary Stent Sales ($m) Forecast, by Segment, 2011-2020
  • Table 163: Global DES Sales ($m) Forecast, 2011-2020
  • Table 164: Global BMS Sales ($m) Forecast, 2011-2020
  • Table 165: EU Coronary Stent Sales ($m) Forecast, by Segment, 2011-2020
  • Table 166: Coronary Stents Market Sales ($m) Forecast for France, 2011-2020
  • Table 167: Coronary Stents Market Sales ($m) Forecast for Germany, 2011-2020
  • Table 168: Coronary Stents Market Sales ($m) Forecast for Italy, 2011-2020
  • Table 169: Coronary Stents Market Sales ($m) Forecast for Spain, 2011-2020
  • Table 170: Coronary Stents Market Sales ($m) Forecast for the UK, 2011-2020
  • Table 171: Primary Research Interviews Completed
  • Table 172: Physicians Surveyed, By Country

List of Figures

  • Figure 1: Pathophysiology of CAD
  • Figure 2: CAD Treatment Modalities
  • Figure 3: Percentage of Patients with CAD Who Receive Each Therapy Option Only, Global, 2012 and 2019 (N=58)
  • Figure 4: Percentage of Patients with CAD Who Receive Each Type of PCI Only, Global, 2012 and 2019 (N=58)
  • Figure 5: Types of Stents Used to Treat CAD
  • Figure 6: Example of a BMS
  • Figure 7: Example of a DEB
  • Figure 8: Types of Atherectomy
  • Figure 9: 5EU Coronary Stenting Procedure Volume, 2011-2020
  • Figure 10: US Mean Hospital Costs* ($US) for Cardiac Revascularization Procedures, 2011-2020
  • Figure 11: Percentage of CAD Patients with ISR, Global, 2012 and 2018 (N=58)
  • Figure 12: Percentage of CAD Patients Who Receive Stent-In-Stent Procedures, Global, 2012 and 2018 (N=58)
  • Figure 13: Interventional Cardiologists' Ranking of the Importance of Each Therapy Attribute in Adopting Stents for the Treatment of CAD, Global, 2013 (N=101)
  • Figure 14: Global Coronary Stents Market Value Share (%), 2013 and 2020
  • Figure 15: EU Market Share for BMS (%), 2013
  • Figure 16: EU Market Share for DES (%), 2013
  • Figure 17: Global Coronary Stent Pipeline Products by Stage of Development, 2014
  • Figure 18: Global Coronary Stents Market Revenue ($m), 2011-2020
  • Figure 19: Global DES Market Revenue ($m), 2011-2020
  • Figure 20: Global BMS Market Revenue ($m), 2011-2020
  • Figure 21: Percentage of Patients (%) Treated with Each Type of Coronary Stent Only, Global, 2013 and 2020 (N=101)
  • Figure 22: Percentage of Patients (%) Treated with Coronary Stents for Each Indication, Global, 2013 and 2020 (N=101)
  • Figure 23: EU Sales ($m) Forecast for Coronary Stents, 2011-2020
  • Figure 24: French Sales ($m) Forecast for Coronary Stents, 2011-2020
  • Figure 25: German Sales ($m) Forecast for Coronary Stents, 2011-2020
  • Figure 26: Italian Sales ($m) Forecast for Coronary Stents, 2011-2020
  • Figure 27: Spanish Sales ($m) Forecast for Coronary Stents, 2011-2020
  • Figure 28: UK Sales ($m) Forecast for Coronary Stents, 2011-2020
Back to Top